From Discovery to Clinical Reality
[ R&D Innovation Pipeline ]Our 5-phase genomics pipeline integrates AI, multi-omics and precision medicine to accelerate breakthroughs from lab bench to patient bedside.
Discovery & Target ID
Multi-Omics Data AcquisitionIntegrating genomics, transcriptomics, proteomics and metabolomics to identify high-confidence disease targets using our proprietary AI engine.
Lead Identification
High-Throughput ScreeningScreening thousands of molecular candidates using in-silico platforms and AI-driven hit-to-lead optimization for potency and selectivity.
Preclinical Research
Safety & Efficacy ValidationRigorous toxicology, pharmacokinetics and pharmacodynamics evaluation. Genomic biomarker development for patient stratification.
Clinical Investigation
Precision Trial DesignAI-stratified patient cohorts in Phase I–III trials. Real-world genomic data monitoring and adaptive trial design for maximum efficacy.
Regulatory & Launch
NDA / BLA SubmissionAccelerated regulatory pathways for rare diseases and precision oncology. Post-market Phase IV genomic surveillance programs.
| Phase | Focus | Projects | Status |
|---|---|---|---|
| Phase 01 | Discovery & Target ID | 14 projects | Active |
| Phase 02 | Lead Identification | 9 projects | Active |
| Phase 03 | Preclinical Research | 6 projects | In Progress |
| Phase 04 | Clinical Investigation | 4 projects | Phase II |
| Phase 05 | Regulatory & Launch | 2 projects | Upcoming |
Science That Changes Lives
[ Breakthrough Discoveries ]From AI-predicted cancer treatments to rare disease atlases — our research is rewriting the boundaries of what genomic medicine can achieve.
AI-Predicted Cancer Treatment Protocol
First-in-Human AI Oncology CandidateGeneMatrix's proprietary AI engine analyzed 2.4 million genomic profiles to predict the optimal treatment protocol for triple-negative breast cancer — achieving a 95% remission rate in Phase II trials, surpassing all prior benchmarks.
Key Milestones- AI model trained on 2.4M genomic profiles
- Phase II trial: 95% remission rate achieved
- FDA Breakthrough Therapy Designation granted
- Published in Nature Medicine (2025)
Rare Disease Gene Discovery Atlas
47 Novel Genetic Markers IdentifiedUsing multi-omics fusion and AI-driven biomarker mapping, our team identified 47 previously unknown genetic markers across 12 rare diseases — opening new therapeutic pathways for over 100,000 patients globally who had no prior treatment options.
Key Milestones- Multi-omics data fusion across 18 biobanks
- 47 novel markers validated in 3 independent cohorts
- Partnered with NIH Rare Diseases Consortium
- Awarded $12M NIH research grant
AI Immunotherapy Response Predictor
89% Accuracy — 29% Above Industry StandardOur AI-powered radiomics platform achieved 89% accuracy in predicting immunotherapy responses — a 29% improvement over conventional methods. The system identifies up to 17% more responders for rare cancers, dramatically improving patient selection for clinical trials.
Key Milestones- Radiomics AI trained on 850K+ imaging datasets
- 89% accuracy validated across 6 cancer types
- Trial participation rate increased from 4% to 18%
- CE Mark & FDA 510(k) clearance obtained
World's Largest Pharmacogenomic Database
500,000+ Drug-Gene Interactions CataloguedWe launched the world's most comprehensive pharmacogenomic database — cataloguing over 500,000 drug-gene interactions across 1,200 medications. This platform now powers personalized medication decisions for 3.2 million patients across 40 countries.
Key Milestones- 500,000+ interactions validated by clinical pharmacists
- Integrated with 120+ hospital EHR systems globally
- Reduced adverse drug events by 34% in pilot hospitals
- Named "Innovation of the Year" — ASHP 2023
Patent Portfolio
Protecting innovation and intellectual property
| Patent ID | Title | Status | Year | Citations |
|---|---|---|---|---|
| US-2024-001 | AI-Driven Genetic Risk Prediction System | Granted | 2024 | 127 |
| US-2024-002 | Quantum Genomic Sequencing Method | Granted | 2024 | 89 |
| US-2023-045 | Blockchain-Based Health Data Storage | Granted | 2023 | 156 |
| US-2023-078 | Real-Time Genetic Expression Monitor | Granted | 2023 | 203 |
| US-2025-012 | Neural Network for Drug Interaction Prediction | Pending | 2025 | 0 |
| US-2025-019 | Wearable Genomic Sensor Technology | Pending | 2025 | 0 |
Join Our Research Network
Collaborate with us on groundbreaking genomic research and innovation projects